Physician profile
Thomas A Harrington
NPI 1629081716
$3,794.36
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $1,350 · 2021: $1,028.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $558.46 | 2019-2021 | |
| Novo Nordisk INC | $370.46 | 2019-2021 | |
| Amgen INC. | $346.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $346.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.07 | 2019-2021 | |
| Lilly USA, LLC | $201.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $157.48 | 2019-2021 | |
| Abbvie INC. | $148.28 | 2019-2021 | |
| Pfizer INC. | $118.27 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $102.97 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $99.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $73.76 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Esperion Therapeutics, INC. | $70.44 | 2020-2021 | |
| Radius Health, INC. | $70.18 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.63 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $60.60 | 2021 | |
| Astellas Pharma US INC | $57.68 | 2019 | |
| Allergan, INC. | $51.41 | 2020 | |
| Lundbeck LLC | $48.35 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.83 | 2021 | |
| Sanofi Pasteur INC. | $31.58 | 2019-2020 | |
| Amarin Pharma, INC. | $31.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.36 | 2020 | |
| Clarus Therapeutics INC. | $28.22 | 2021 | |
| Ibsa Pharma INC. | $23.78 | 2021 | |
| Dexcom, INC. | $22.74 | 2021 | |
| Mylan Specialty L.P. | $21.86 | 2020 | |
| Ortho-Clinical Diagnostics, INC. | $17.89 | 2019 | |
| Abbott Laboratories | $16.05 | 2020 | |
| Insulet Corporation | $15.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.60 | 2019 | |
| Gilead Sciences, INC. | $14.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.66 | 2019 | |
| Eisai INC. | $12.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.